Trial Profile

An Open-Label Phase 1b/2 Study of E7389 Liposomal Formulation Plus Nivolumab in Subjects With Solid Tumor

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eribulin (Primary) ; Nivolumab (Primary)
Indications Gastric cancer; Oesophageal cancer; Small cell lung cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Eisai Inc

Most Recent Events

10 Dec 2024 The protocol has been amended to change in time frame for its primary endpoint Phase 2: ORR time_frame: Baseline up to End of Treatment (Up to approximately 65 months).
10 Dec 2024 Planned End Date changed from 31 Jan 2024 to 31 Mar 2026.
10 Dec 2024 Planned primary completion date changed from 31 Jan 2024 to 31 Mar 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com